Evidence map›Paper›PMID 31113680›Full record

ArticleGynecologic oncology2019

Brain metastasis in epithelial ovarian cancer by BRCA1/2 mutation status.

Marina Stasenko, Paulina Cybulska, Noah Feit, Vicky Makker, Jason Konner, Roisin E O'Cearbhaill, Kaled M Alektiar, Kathryn Beal, Ginger J Gardner, Kara C Long Roche and 6 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Gynecologic oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
2.1field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 35 citations in OpenAlex.

  1. Article
  2. Article
  3. Observational
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Therapeutic Options for Brain Metastases in Gynecologic Cancers.Current treatment options in oncology · 2022
    Review
  11. Article
  12. Article
  13. Tumor-Derived Exosomes Modulate Primary Site Tumor Metastasis.Frontiers in cell and developmental biology · 2022
    Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 2 institutions in 1 country.

Marina StasenkoDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Paulina CybulskaDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Noah FeitWeill Cornell Medical College of Cornell University, New York, NY 10065, USA.
Vicky MakkerWeill Cornell Medical College of Cornell University, New York, NY 10065, USA; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Jason KonnerWeill Cornell Medical College of Cornell University, New York, NY 10065, USA; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Roisin E O'CearbhaillWeill Cornell Medical College of Cornell University, New York, NY 10065, USA; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Kaled M AlektiarWeill Cornell Medical College of Cornell University, New York, NY 10065, USA; Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Kathryn BealWeill Cornell Medical College of Cornell University, New York, NY 10065, USA; Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Ginger J GardnerDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Weill Cornell Medical College of Cornell University, New York, NY 10065, USA.
Kara C Long RocheDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Weill Cornell Medical College of Cornell University, New York, NY 10065, USA.
Yukio SonodaDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Weill Cornell Medical College of Cornell University, New York, NY 10065, USA.
Dennis S ChiDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Weill Cornell Medical College of Cornell University, New York, NY 10065, USA.
Oliver ZivanovicDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Weill Cornell Medical College of Cornell University, New York, NY 10065, USA.
Mario M LeitaoDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Weill Cornell Medical College of Cornell University, New York, NY 10065, USA.
Karen A CadooWeill Cornell Medical College of Cornell University, New York, NY 10065, USA; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
William P TewWeill Cornell Medical College of Cornell University, New York, NY 10065, USA; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. Electronic address: teww@mskcc.org.
Cornell University · USMemorial Sloan Kettering Cancer Center · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

objectiveTo evaluate clinical outcomes of patients with BRCA-associated ovarian cancer who developed brain metastases (BM).

methodsPatients with epithelial ovarian, fallopian tube, and primary peritoneal cancer (EOC) and BM, treated at a single institution from 1/1/2008-7/1/2018, were identified from two institutional databases. Charts and medical records were retrospectively reviewed for clinical characteristics and germline BRCA mutation status. Appropriate statistics were used.

resultsOf 3649 patients with EOC, 91 had BM (2.5%). Germline mutation status was available for 63 (69%) cases; 21 (35%) of these harbored a BRCA1/2 mutation (15 BRCA1, 6 BRCA2). Clinical characteristics were similar between groups. BM were diagnosed at a median of 31 months (95% CI, 22.6-39.4) in BRCA-mutated (mBRCA) and 32 months (95% CI, 23.7-40.3) in wild-type BRCA (wtBRCA) (p = 0.78) patients. Brain metastases were the only evidence of disease at time of BM diagnoses in 48% (n = 10) mBRCA and 19% (n = 8) wtBRCA (p = 0.02) patients. There was no difference in treatment of BM by mutation status (p = 0.84). Survival from time of BM diagnosis was 29 months (95%CI, 15.5-42.5) in mBRCA and 9 months (95% CI, 5.5-12.5) in wtBRCA patients, with an adjusted hazard ratio (HR) of 0.53, p = 0.09; 95% CI, 0.25-1.11. HR was adjusted for presence of systemic disease at time of BM diagnosis.

conclusionThis is the largest study to date comparing outcomes in patients with EOC and BM by mutation status. mBRCA patients were more likely to have isolated BM, which may be a factor in their long survival. This supports the pursuit of aggressive treatment for mBRCA EOC patients with BM. Additional studies examining the correlation of BRCA mutational status with BM are warranted.

Indexed as

Genes, BRCA1Genes, BRCA2Germ-Line MutationAdultAgedAged, 80 and overBrain NeoplasmsBRCA1 ProteinBRCA2 ProteinCarcinoma, Ovarian EpithelialFemaleGenetic Predisposition to DiseaseHumansMiddle AgedRetrospective StudiesBRCA1 ProteinBRCA1 protein, humanBRCA2 ProteinBRCA2 protein, humanBrain metastasisBRCA mutationOvarian cancer

Identifiers

PMID31113680
PMCPMC6589378
OpenAlexW2946432630

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.